erythromycin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 1048 114-07-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • erythromycin gluceptate
  • erythromycin lactobionate
  • erythromycin stearate
  • erythromycin
  • Erythromycin A
  • erythrocin
  • erythromycin phosphate
  • erythromycin thiocyanate
A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.
  • Molecular weight: 733.94
  • Formula: C37H67NO13
  • CLOGP: 1.63
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 5
  • TPSA: 193.91
  • ALOGS: -3.20
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O
2 g O
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 90.88 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 35 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.95 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 24, 1964 FDA ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4895.11 12.29 2234 18180 248776 50335934
International normalised ratio fluctuation 198.30 12.29 61 20353 2129 50582581
Bloody discharge 129.14 12.29 38 20376 1136 50583574
Lyme disease 93.14 12.29 36 20378 2507 50582203
Seronegative arthritis 89.34 12.29 33 20381 2028 50582682
Exposure during pregnancy 66.33 12.29 149 20265 120866 50463844
Necrosis ischaemic 62.89 12.29 20 20394 779 50583931
Anaphylactic reaction 60.93 12.29 91 20323 53964 50530746
Wheezing 51.60 12.29 91 20323 61956 50522754
Dislocation of vertebra 51.25 12.29 25 20389 3062 50581648
Faecal volume decreased 50.77 12.29 12 20402 148 50584562
Beta haemolytic streptococcal infection 50.06 12.29 21 20393 1809 50582901
Pneumonia streptococcal 48.96 12.29 20 20394 1611 50583099
Drug interaction 48.01 12.29 183 20231 199438 50385272
Amniotic cavity infection 44.51 12.29 17 20397 1146 50583564
Vomiting 42.95 12.29 325 20089 460433 50124277
Rash 39.87 12.29 307 20107 437164 50147546
Pneumococcal infection 39.52 12.29 12 20402 400 50584310
Ototoxicity 37.91 12.29 15 20399 1112 50583598
Completed suicide 36.44 12.29 5 20409 131884 50452826
Umbilical erythema 36.14 12.29 8 20406 72 50584638
Death 35.14 12.29 48 20366 325331 50259379
Vertigo positional 34.82 12.29 18 20396 2493 50582217
Abortion spontaneous 34.37 12.29 61 20353 41711 50542999
Drug intolerance 33.80 12.29 176 20238 218928 50365782
Purpura senile 32.58 12.29 11 20403 518 50584192
Death neonatal 32.19 12.29 9 20405 223 50584487
Caesarean section 31.30 12.29 35 20379 15604 50569106
Spondylitis 30.09 12.29 17 20397 2808 50581902
Bronchial obstruction 29.36 12.29 13 20401 1277 50583433
Tarsal tunnel syndrome 28.50 12.29 10 20404 529 50584181
Pain 28.24 12.29 129 20285 578774 50005936
Premature baby 26.82 12.29 35 20379 18302 50566408
Mass excision 26.51 12.29 8 20406 261 50584449
Drug tolerance decreased 26.50 12.29 25 20389 9135 50575575
Stevens-Johnson syndrome 26.49 12.29 38 20376 21714 50562996
Serum sickness-like reaction 25.91 12.29 9 20405 462 50584248
Fall 25.74 12.29 61 20353 334871 50249839
Wound infection 25.71 12.29 28 20386 12120 50572590
Lip swelling 25.54 12.29 40 20374 24696 50560014
Therapeutic product effect incomplete 24.56 12.29 87 20327 91428 50493282
Oligohydramnios 23.29 12.29 19 20395 5731 50578979
Breast cancer stage III 22.85 12.29 15 20399 3241 50581469
Infection 22.67 12.29 133 20281 172821 50411889
Premature rupture of membranes 22.58 12.29 17 20397 4563 50580147
Resorption bone increased 22.41 12.29 10 20404 1001 50583709
Spinal fusion surgery 22.34 12.29 16 20398 3979 50580731
Adjustment disorder with depressed mood 22.31 12.29 14 20400 2800 50581910
Abdominal pain upper 21.85 12.29 124 20290 159185 50425525
Drug ineffective 20.86 12.29 221 20193 819112 49765598
Vestibular disorder 20.24 12.29 10 20404 1259 50583451
Mucous stools 19.47 12.29 13 20401 2889 50581821
Ergot poisoning 19.09 12.29 5 20409 96 50584614
Pharyngeal oedema 19.05 12.29 25 20389 13140 50571570
Maternal drugs affecting foetus 18.94 12.29 16 20398 5061 50579649
Urticaria 18.53 12.29 102 20312 129459 50455251
Corneal neovascularisation 18.49 12.29 5 20409 109 50584601
Corneal perforation 18.28 12.29 7 20407 475 50584235
Acute generalised exanthematous pustulosis 17.88 12.29 20 20394 8918 50575792
Stenotrophomonas infection 17.66 12.29 10 20404 1659 50583051
Nasopharyngitis 17.44 12.29 32 20382 192895 50391815
Alopecia 16.97 12.29 47 20367 245000 50339710
Infantile haemangioma 16.32 12.29 4 20410 58 50584652
Starvation ketoacidosis 15.90 12.29 4 20410 65 50584645
Febrile neutropenia 15.71 12.29 10 20404 97657 50487053
Anal candidiasis 15.63 12.29 3 20411 12 50584698
Type 2 diabetes mellitus 15.21 12.29 39 20375 34336 50550374
Cardiac arrest neonatal 14.39 12.29 4 20410 97 50584613
Hypersensitivity 14.28 12.29 141 20273 215020 50369690
Prescribed overdose 14.23 12.29 23 20391 14577 50570133
Stomatitis 14.19 12.29 12 20402 101332 50483378
Neutropenia 13.85 12.29 24 20390 147941 50436769
Dysphoria 13.75 12.29 13 20401 4761 50579949
Product packaging issue 13.60 12.29 7 20407 960 50583750
Toxicity to various agents 13.10 12.29 43 20371 212456 50372254
Stillbirth 13.09 12.29 14 20400 5938 50578772
Ill-defined disorder 13.07 12.29 3 20411 54651 50530059
Anaemia 13.01 12.29 55 20359 252401 50332309
Pseudomembranous colitis 12.99 12.29 10 20404 2775 50581935
Premature delivery 12.78 12.29 29 20385 23634 50561076
Blepharitis 12.76 12.29 9 20405 2186 50582524
Renal impairment neonatal 12.62 12.29 3 20411 38 50584672
Abdominal pain 12.52 12.29 148 20266 236080 50348630
Haemoglobin decreased 12.50 12.29 20 20394 127196 50457514
Fatigue 12.41 12.29 206 20208 707395 49877315

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 488.24 15.30 280 8194 68126 29497927
Hyphaema 74.49 15.30 19 8455 469 29565584
Toxic epidermal necrolysis 68.48 15.30 50 8424 18103 29547950
Product packaging issue 62.84 15.30 17 8457 530 29565523
Drug interaction 61.49 15.30 158 8316 197227 29368826
Premature baby 44.46 15.30 38 8436 17242 29548811
Dystonia 44.06 15.30 30 8444 9719 29556334
Stupor 39.16 15.30 18 8456 2726 29563327
Rhabdomyolysis 35.52 15.30 63 8411 60745 29505308
Obstruction gastric 34.75 15.30 12 8462 858 29565195
Acute generalised exanthematous pustulosis 34.69 15.30 21 8453 5562 29560491
Coagulation time prolonged 34.47 15.30 13 8461 1197 29564856
Intraocular pressure increased 32.32 15.30 19 8455 4770 29561283
Foetal death 31.26 15.30 8 8466 200 29565853
Eye pain 30.85 15.30 26 8448 11569 29554484
Brain oedema 29.66 15.30 26 8448 12194 29553859
Deafness bilateral 29.52 15.30 11 8463 980 29565073
SAPHO syndrome 28.86 15.30 6 8468 57 29565996
Pyloric stenosis 28.62 15.30 10 8464 740 29565313
Product dispensing error 27.49 15.30 18 8456 5462 29560591
Foetal arrhythmia 25.86 15.30 6 8468 98 29565955
Caesarean section 25.53 15.30 12 8462 1911 29564142
Oligohydramnios 23.59 15.30 7 8467 306 29565747
Oculogyric crisis 22.84 15.30 10 8464 1351 29564702
Onychophagia 22.69 15.30 5 8469 64 29565989
Maternal drugs affecting foetus 22.54 15.30 14 8460 3879 29562174
Low birth weight baby 22.22 15.30 17 8457 6591 29559462
Learning disorder 22.13 15.30 9 8465 1013 29565040
Febrile neutropenia 22.09 15.30 3 8471 112237 29453816
Ototoxicity 21.50 15.30 10 8464 1555 29564498
Tricuspid valve disease 21.48 15.30 6 8468 211 29565842
Respiratory acidosis 21.18 15.30 14 8460 4314 29561739
Sepsis neonatal 20.67 15.30 6 8468 243 29565810
Myasthenia gravis crisis 20.49 15.30 7 8467 484 29565569
Vasculitic rash 20.08 15.30 8 8466 853 29565200
Torsade de pointes 19.94 15.30 16 8458 6645 29559408
Pathogen resistance 19.16 15.30 17 8457 8099 29557954
Swelling face 18.72 15.30 26 8448 20324 29545729
Hepatic necrosis 18.66 15.30 12 8462 3530 29562523
Accidental exposure to product 18.66 15.30 19 8455 10734 29555319
Ischaemic hepatitis 18.54 15.30 9 8465 1539 29564514
Potentiating drug interaction 18.50 15.30 13 8461 4425 29561628
Myoglobinuria 17.84 15.30 7 8467 717 29565336
Hepatic failure 17.55 15.30 32 8442 31480 29534573
Measles 17.53 15.30 5 8469 190 29565863
Cardio-respiratory arrest neonatal 17.32 15.30 3 8471 9 29566044
Neonatal disorder 17.14 15.30 7 8467 796 29565257
Stevens-Johnson syndrome 16.58 15.30 22 8452 16475 29549578
Exposure during pregnancy 16.48 15.30 16 8458 8538 29557515
Brain herniation 15.98 15.30 11 8463 3622 29562431
Pupillary disorder 15.92 15.30 5 8469 265 29565788
Megacolon 15.31 15.30 8 8466 1597 29564456

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 3374.10 12.14 1652 21618 236163 64239299
International normalised ratio fluctuation 190.94 12.14 62 23208 2899 64472563
Bloody discharge 128.99 12.14 39 23231 1438 64474024
Drug interaction 100.83 12.14 323 22947 361760 64113702
Lyme disease 98.87 12.14 36 23234 2379 64473083
Product packaging issue 77.59 12.14 24 23246 956 64474506
Seronegative arthritis 69.96 12.14 29 23241 2714 64472748
Hyphaema 64.60 12.14 19 23251 636 64474826
Necrosis ischaemic 61.01 12.14 20 23250 963 64474499
Toxic epidermal necrolysis 59.16 12.14 70 23200 37096 64438366
Beta haemolytic streptococcal infection 51.62 12.14 21 23249 1873 64473589
Dislocation of vertebra 50.54 12.14 24 23246 3100 64472362
Ototoxicity 50.52 12.14 23 23247 2700 64472762
Pneumonia streptococcal 50.24 12.14 22 23248 2356 64473106
Anaphylactic reaction 47.14 12.14 87 23183 68577 64406885
Wheezing 45.48 12.14 94 23176 80485 64394977
Stevens-Johnson syndrome 42.55 12.14 57 23213 34192 64441270
Exposure during pregnancy 40.80 12.14 88 23182 77587 64397875
Acute generalised exanthematous pustulosis 37.70 12.14 35 23235 14023 64461439
Pneumococcal infection 36.46 12.14 13 23257 808 64474654
Febrile neutropenia 35.01 12.14 12 23258 187645 64287817
Drug intolerance 34.67 12.14 147 23123 187845 64287617
Drug abuse 33.88 12.14 4 23266 132370 64343092
Stupor 33.41 12.14 23 23247 6012 64469450
Completed suicide 33.08 12.14 20 23250 224394 64251068
Drug tolerance decreased 32.58 12.14 24 23246 6974 64468488
Death 32.11 12.14 80 23190 482625 63992837
Caesarean section 32.05 12.14 29 23241 11245 64464217
Vertigo positional 31.39 12.14 17 23253 2894 64472568
Rash 30.96 12.14 276 22994 458273 64017189
Maternal exposure during pregnancy 30.71 12.14 90 23180 95794 64379668
Tarsal tunnel syndrome 30.24 12.14 10 23260 495 64474967
Purpura senile 30.12 12.14 10 23260 501 64474961
Infection 28.41 12.14 137 23133 184743 64290719
Coagulation time prolonged 27.31 12.14 14 23256 2132 64473330
Intraocular pressure increased 26.89 12.14 23 23247 8279 64467183
Lip swelling 26.53 12.14 44 23226 31863 64443599
Torsade de pointes 26.47 12.14 32 23238 17331 64458131
Deafness bilateral 26.10 12.14 13 23257 1863 64473599
Breast cancer stage III 25.97 12.14 15 23255 2890 64472572
Learning disorder 25.60 12.14 9 23261 537 64474925
Serum sickness-like reaction 25.53 12.14 9 23261 541 64474921
Adjustment disorder with depressed mood 25.52 12.14 14 23256 2443 64473019
Respiratory acidosis 25.39 12.14 24 23246 9831 64465631
Oligohydramnios 24.96 12.14 15 23255 3109 64472353
Therapeutic product effect incomplete 23.99 12.14 87 23183 103395 64372067
Bronchial obstruction 23.22 12.14 13 23257 2361 64473101
Spinal fusion surgery 22.81 12.14 15 23255 3636 64471826
Ergot poisoning 22.63 12.14 6 23264 136 64475326
Spondylitis 22.56 12.14 14 23256 3072 64472390
Premature rupture of membranes 22.47 12.14 15 23255 3729 64471733
Oculogyric crisis 22.41 12.14 13 23257 2525 64472937
Product dispensing error 22.37 12.14 24 23246 11426 64464036
Mass excision 22.36 12.14 7 23263 290 64475172
Corneal neovascularisation 22.27 12.14 6 23264 145 64475317
SAPHO syndrome 22.15 12.14 6 23264 148 64475314
Resorption bone increased 22.09 12.14 10 23260 1158 64474304
Wound infection 22.02 12.14 27 23243 14837 64460625
Anaemia 21.28 12.14 68 23202 378612 64096850
Pharyngeal oedema 21.07 12.14 27 23243 15504 64459958
Fall 20.64 12.14 79 23191 416747 64058715
Malignant neoplasm progression 19.73 12.14 8 23262 112863 64362599
Eye pain 19.14 12.14 38 23232 31587 64443875
Haemoglobin decreased 18.53 12.14 26 23244 195037 64280425
Dystonia 18.42 12.14 28 23242 18837 64456625
Vomiting 18.08 12.14 289 22981 550828 63924634
Asthenia 17.61 12.14 87 23183 427957 64047505
Swelling face 17.49 12.14 54 23216 59112 64416350
Tricuspid valve disease 16.63 12.14 6 23264 386 64475076
Neutropenia 16.46 12.14 39 23231 239585 64235877
Rhabdomyolysis 16.32 12.14 71 23199 91655 64383807
Vestibular disorder 15.75 12.14 10 23260 2283 64473179
Abdominal pain upper 15.38 12.14 112 23158 174918 64300544
Ulcerative keratitis 15.28 12.14 11 23259 3086 64472376
Anal candidiasis 15.25 12.14 3 23267 16 64475446
Type 2 diabetes mellitus 15.02 12.14 36 23234 33984 64441478
Myasthenia gravis crisis 14.94 12.14 7 23263 877 64474585
Potentiating drug interaction 14.54 12.14 16 23254 7836 64467626
Live birth 14.45 12.14 19 23251 11185 64464277
Pathogen resistance 14.25 12.14 20 23250 12523 64462939
Starvation ketoacidosis 14.18 12.14 4 23266 115 64475347
Dermatitis allergic 14.15 12.14 22 23248 15087 64460375
Myoglobinuria 14.12 12.14 7 23263 993 64474469
Urticaria 13.95 12.14 96 23174 147221 64328241
Brain oedema 13.94 12.14 27 23243 22048 64453414
Grip strength decreased 13.78 12.14 19 23251 11705 64463757
Walking aid user 13.76 12.14 14 23256 6267 64469195
Hypotension 13.69 12.14 81 23189 380893 64094569
Cardiac arrest neonatal 13.60 12.14 3 23267 30 64475432
Maternal drugs affecting foetus 13.52 12.14 8 23262 1612 64473850
Platelet count decreased 13.44 12.14 25 23245 167686 64307776
Corneal perforation 13.39 12.14 6 23264 678 64474784
Premature delivery 13.31 12.14 24 23246 18565 64456897
Amniotic cavity infection 12.68 12.14 6 23264 768 64474694
Abortion spontaneous 12.64 12.14 28 23242 25115 64450347
Nasopharyngitis 12.61 12.14 33 23237 196040 64279422
Clostridium colitis 12.53 12.14 9 23261 2516 64472946
Pupillary disorder 12.26 12.14 5 23265 449 64475013
Drug resistance 12.25 12.14 34 23236 35068 64440394
Abdominal rigidity 12.21 12.14 9 23261 2618 64472844
Documented hypersensitivity to administered product 12.16 12.14 6 23264 842 64474620

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D10AF02 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Antiinfectives for treatment of acne
ATC D10AF52 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Antiinfectives for treatment of acne
ATC J01FA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Macrolides
ATC S01AA17 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0028311 Macrolides
FDA PE N0000009982 Decreased Sebaceous Gland Activity
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
FDA EPC N0000175877 Macrolide
FDA EPC N0000175935 Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Listeriosis indication 4241002 DOID:11573
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Pertussis indication 27836007
Acute gonococcal urethritis indication 29864006
Neonatal conjunctivitis indication 34298002 DOID:9699
Gonorrhea of rectum indication 42746002
Pneumonia due to Mycoplasma pneumoniae indication 46970008
Bacterial pneumonia indication 53084003 DOID:874
Acute gonococcal endometritis indication 65295003 DOID:7527
Acute bacterial sinusitis indication 75498004
Syphilis indication 76272004
Pneumococcal pharyngitis indication 76651006
Nongonococcal urethritis indication 84619001
Acne vulgaris indication 88616000
Urethritis due to Chlamydia trachomatis indication 179101003
Chlamydial conjunctivitis indication 231861005 DOID:13800
Pneumococcal pneumonia indication 233607000
Chlamydial pneumonia indication 233609002
Neonatal pneumonia indication 233619008
Erythrasma indication 238418005 DOID:4131
Streptococcus pyogenes infection indication 302809008
Infective otitis media indication 312218008
Diphtheria indication 397428000
Infection due to Staphylococcus aureus indication 406602003
Recurrent Persistent Urethritis indication
Superficial Ocular Infection indication
Preoperative Bowel Preparation indication
Prevention of Bacterial Endocarditis indication
Chlamydia Cervicitis indication
Rectal Chlamydia Trachomatis Infection indication
Prevention of Neonatal Ophthalmia indication
Pneumococcal Acute Otitis Media indication
Legionnaires' Disease indication
Rheumatic Fever Prevention indication
Haemophilus Influenzae Acute Otitis Media indication
Trachoma off-label use 2576002 DOID:11265
Inhalational anthrax off-label use 11389007
Actinomycotic infection off-label use 11817007 DOID:8478
Enteric campylobacteriosis off-label use 18081009
Lyme disease off-label use 23502006 DOID:11729
Granuloma inguinale off-label use 28867007 DOID:9113
Sinusitis off-label use 36971009
Erysipelas off-label use 44653001 DOID:11330
Blepharoconjunctivitis off-label use 68659002 DOID:2456
Cutaneous anthrax off-label use 84980006 DOID:7426
Ecthyma off-label use 85791004
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Bacterial conjunctivitis off-label use 128350005 DOID:9700
Bacterial infection of skin off-label use 128936008
Lymphogranuloma venereum off-label use 186946009 DOID:13819
Gastroesophageal reflux disease off-label use 235595009 DOID:8534
Gastroparesis off-label use 235675006
Chancroid off-label use 266143009 DOID:13778
Meibomianitis off-label use 309779001
Infective blepharitis off-label use 312219000
Bacterial keratitis off-label use 314557000
Erysipeloid off-label use 400105005
Anthrax off-label use 409498004 DOID:7427
Relapsing fever off-label use 420079008 DOID:13034
Gastroscopy Adjunct off-label use
Listeria Monocytogenes Septicemia off-label use
Ureaplasma Pneumonia off-label use
Torsades de pointes contraindication 31722008
Third trimester pregnancy contraindication 41587001
Megaloblastic anemia due to folate deficiency contraindication 85649008 DOID:14026
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Cholestatic hepatitis contraindication 95556007
Anemia due to enzyme deficiency contraindication 111577008
Prolonged QT interval contraindication 111975006
Hearing disorder contraindication 128540005
Liver function tests abnormal contraindication 166603001
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000
Erythroderma contraindication 399992009
Porphyria contraindication 418470004
Congenital long QT syndrome contraindication 442917000
Inflammatory dermatosis contraindication 703938007




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Cats Bacterial pneumonia Indication
Cats Upper respiratory infections Indication
Cats Secondary infections associated with panleukopenia Indication
Cats Bacterial wound infections caused by Staphylococcus species Indication
Cats Bacterial wound infections caused by Streptococcus species Indication
Cattle Bovine respiratory disease (BRD) associated with Pasturella multiocida Indication
Cattle Mastitis caused by Staphylococcus aureus Indication
Cattle Mastitis caused by Streptococcus dysgalactiae Indication
Cattle Mastitis caused by Streptococcus dysgalactiae Indication
Cattle Mastitis caused by Streptococcus uberis Indication
Chickens Prevention and reduction of lesions and in lowering severity of chronic respiratory disease Indication
Chickens Prevention of infectious coryza Indication
Chickens Prevention of chronic respiratory disease during periods of stress Indication
Chickens Chronic respiratory disease caused by Mycoplasma gallisepticum Indication
Chickens Infectious coryza caused by Hemophilus gallinarum Indication
Dogs Bacterial pneumonia Indication
Dogs upper respiratory infections Indication
Dogs Endometritis and metritis Indication
Dogs Bacterial wound infections caused by Staphylococcus species Indication
Dogs Bacterial wound infections caused by Streptococcus species Indication
Dogs Bacterial wound infections caused by Corynebacterium species Indication
Turkeys Chronic respiratory disease during periods of stress Indication
Turkeys Prevention and reduction of lesions and in lowering severity of chronic respiratory disease Indication
Turkeys Control of blue comb (nonspecific infectious enteritis) Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Gallimycin-100P Bimeda Animal Health Limited 1
Erythro - 100, 200, Gallimycin-100 Bimeda Animal Health Limited 1
Gallimycin PFC Bimeda Animal Health Limited 1
Erythro-36 Dry, Gallimycin-36 Dry Bimeda Animal Health Limited 1
Gallimycin-36 Sterile Bimeda Animal Health Limited 1
Erythromast 36 Zoetis Inc. 1
Erythro-100 Injection Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
250MG ERYTHROMYCIN TORRENT A211975 July 26, 2021 RX TABLET, DELAYED RELEASE ORAL April 2, 2022 COMPETITIVE GENERIC THERAPY
500MG ERYTHROMYCIN TORRENT A211975 July 26, 2021 RX TABLET, DELAYED RELEASE ORAL April 2, 2022 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 7.41 CHEMBL
Aldehyde oxidase Enzyme IC50 4.82 WOMBAT-PK
Bile salt export pump Transporter IC50 5.39 CHEMBL
Motilin receptor GPCR Ki 4.43 CHEMBL
Cytochrome P450 1B1 Enzyme IC50 4.40 CHEMBL

External reference:

IDSource
4017594 VUID
N0000145975 NUI
D00140 KEGG_DRUG
4017591 VANDF
4017594 VANDF
4017595 VANDF
4017596 VANDF
C0014806 UMLSCUI
CHEBI:42355 CHEBI
ERY PDB_CHEM_ID
CHEMBL2110577 ChEMBL_ID
CHEMBL532 ChEMBL_ID
CHEMBL1200506 ChEMBL_ID
CHEMBL3545060 ChEMBL_ID
CHEMBL1200510 ChEMBL_ID
D004917 MESH_DESCRIPTOR_UI
DB00199 DRUGBANK_ID
C010948 MESH_SUPPLEMENTAL_RECORD_UI
C011462 MESH_SUPPLEMENTAL_RECORD_UI
1456 IUPHAR_LIGAND_ID
C025000 MESH_SUPPLEMENTAL_RECORD_UI
39 INN_ID
4501-00-2 SECONDARY_CAS_RN
7704-67-8 SECONDARY_CAS_RN
63937KV33D UNII
12560 PUBCHEM_CID
24346 RXNORM
33316 MMSL
3627 MMSL
4675 MMSL
4678 MMSL
4679 MMSL
4680 MMSL
4769 MMSL
4799 MMSL
72164 MMSL
d00046 MMSL
002755 NDDF
002758 NDDF
002759 NDDF
002760 NDDF
30427009 SNOMEDCT_US
372694001 SNOMEDCT_US
39152007 SNOMEDCT_US
698006 SNOMEDCT_US
83981000 SNOMEDCT_US
96032005 SNOMEDCT_US
96033000 SNOMEDCT_US
23067-13-2 SECONDARY_CAS_RN
3847-29-8 SECONDARY_CAS_RN
643-22-1 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0093-5571 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0093-5572 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
ERYGEL HUMAN PRESCRIPTION DRUG LABEL 1 0378-8075 GEL 20 mg TOPICAL NDA 18 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0378-8212 GEL 20 mg TOPICAL NDA authorized generic 18 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0404-7191 OINTMENT 5 mg OPHTHALMIC ANDA 18 sections
Erythrocin Lactobionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6476 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 13 sections
Erythrocin Lactobionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6482 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 13 sections
erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 0574-4024 OINTMENT 5 mg OPHTHALMIC ANDA 18 sections
Erythrocin Stearate HUMAN PRESCRIPTION DRUG LABEL 1 10544-594 TABLET, FILM COATED 250 mg ORAL ANDA 23 sections
Erythrocin Stearate HUMAN PRESCRIPTION DRUG LABEL 1 10544-595 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 13668-586 TABLET, DELAYED RELEASE 250 mg ORAL ANDA 25 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 13668-588 TABLET, DELAYED RELEASE 500 mg ORAL ANDA 25 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 13668-606 TABLET, COATED 250 mg ORAL ANDA 14 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 13668-607 TABLET, COATED 500 mg ORAL ANDA 14 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 13985-605 OINTMENT 5 mg OPHTHALMIC ANDA 18 sections
Erythromycin Lactobionate HUMAN PRESCRIPTION DRUG LABEL 1 14789-116 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 24 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-088 CAPSULE, DELAYED RELEASE 250 mg ORAL ANDA 22 sections
ERY-TAB HUMAN PRESCRIPTION DRUG LABEL 1 16590-089 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 27 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-090 OINTMENT 5 mg OPHTHALMIC ANDA 9 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-091 TABLET, FILM COATED 250 mg ORAL ANDA 17 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 17478-070 OINTMENT 5 mg OPHTHALMIC ANDA 19 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 21695-173 OINTMENT 5 mg OPHTHALMIC ANDA 15 sections
ERYTHROMYCIN Base Filmtab HUMAN PRESCRIPTION DRUG LABEL 1 21695-387 TABLET, FILM COATED 250 mg ORAL ANDA 24 sections
ERYTHROMYCIN Base Filmtab HUMAN PRESCRIPTION DRUG LABEL 1 21695-389 TABLET, FILM COATED 500 mg ORAL ANDA 24 sections
ERY-TAB HUMAN PRESCRIPTION DRUG LABEL 1 21695-457 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 23 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 24208-910 OINTMENT 5 mg OPHTHALMIC ANDA 8 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 24338-102 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Erythromycin HUMAN PRESCRIPTION DRUG LABEL 1 24338-104 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Erythrocin Stearate HUMAN PRESCRIPTION DRUG LABEL 1 24338-106 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
ERYTHROMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 24338-120 CAPSULE, DELAYED RELEASE 250 mg ORAL ANDA 27 sections